- Latest available (Revised)
- Point in Time (12/08/2016)
- Original (As adopted by EU)
Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products (recast) (Text with EEA relevance)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
Version Superseded: 03/09/2017
Point in time view as at 12/08/2016.
There are currently no known outstanding effects for the Regulation (EC) No 1223/2009 of the European Parliament and of the Council, ANNEX VI.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
a Not required if concentration is 0,5 % or less and when it is used only for product protection purposes. | ||||||||
b [F1For use as a colorant, see Annex IV, No 143.] | ||||||||
c [F2In case of combined use of zinc oxide and zinc oxide (nano), the sum shall not exceed the limit given in column g.] | ||||||||
d [F3In case of combined use of Titanium Dioxide and Titanium Dioxide (nano), the sum shall not exceed the limit given in column g.] | ||||||||
Reference number | Substance identification | Conditions | Wording of conditions of use and warnings | |||||
---|---|---|---|---|---|---|---|---|
Chemical name/INN/XAN | Name of Common Ingredients Glossary | CAS number | EC number | Product type, body parts | Maximum concentration in ready for use preparation | Other | ||
a | b | c | d | e | f | g | h | i |
[F41 | ] | |||||||
2 | N,N,N-Trimethyl-4-(2-oxoborn-3-ylidenemethyl) anilinium methyl sulfate | Camphor Benzalkonium Methosulfate | 52793-97-2 | 258-190-8 | 6 % | |||
3 | Benzoic acid, 2-hydroxy-, 3,3,5-trimethylcyclohexyl ester/Homosalate | Homosalate | 118-56-9 | 204-260-8 | 10 % | |||
4 | 2-Hydroxy-4-methoxybenzophenone/Oxybenzone | Benzophenone-3 | 131-57-7 | 205-031-5 | 10 % | Contains Benzophenone-3a | ||
5 | Moved or deleted | |||||||
6 | 2-Phenylbenzimidazole-5-sulfonic acid and its potassium, sodium and triethanolamine salts/Ensulizole | Phenylbenzimidazole Sulfonic Acid | 27503-81-7 | 248-502-0 | 8 %(as acid) | |||
7 | 3,3'-(1,4-Phenylenedimethylene) bis(7, 7-dimethyl-2-oxobicyclo-[2.2.1]hept-1-yl-methanesulfonic acid) and its salts/Ecamsule | Terephthalylidene Dicamphor Sulfonic Acid | 92761-26-7, 90457-82-2 | 410-960-6 | 10 %(as acid) | |||
8 | 1-(4-tert-Butylphenyl)-3-(4-methoxyphenyl)propane-1,3-dione/Avobenzone | Butyl Methoxydibenzoylmethane | 70356-09-1 | 274-581-6 | 5 % | |||
9 | alpha-(2-Oxoborn-3-ylidene)-toluene-4-sulphonic acid and its salts | Benzylidene Camphor Sulfonic Acid | 56039-58-8 | 6 % (as acid) | ||||
10 | 2-Cyano-3,3-diphenyl acrylic acid, 2-ethylhexyl ester/Octocrilene | Octocrylene | 6197-30-4 | 228-250-8 | 10 % (as acid) | |||
11 | Polymer of N-{(2 and 4)-[(2-oxoborn-3-ylidene)methyl]benzyl} acrylamide | Polyacrylamidomethyl Benzylidene Camphor | 113783-61-2 | 6 % | ||||
12 | 2-Ethylhexyl 4-methoxycinnamate/Octinoxate | Ethylhexyl Methoxycinnamate | 5466-77-3 | 226-775-7 | 10 % | |||
13 | Ethoxylated ethyl-4-aminobenzoate | PEG-25 PABA | 116242-27-4 | 10 % | ||||
14 | Isopentyl-4-methoxycinnamate/Amiloxate | Isoamyl p-Methoxycinnamate | 71617-10-2 | 275-702-5 | 10 % | |||
15 | 2,4,6-Trianilino-(p-carbo-2'-ethylhexyl-1'-oxy)-1,3,5-triazine | Ethylhexyl Triazone | 88122-99-0 | 402-070-1 | 5 % | |||
16 | Phenol,2-(2H-benzotriazol-2-yl)-4-methyl-6-(2-methyl-3-(1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy)-disiloxanyl)propyl) | Drometrizole Trisiloxane | 155633-54-8 | 15 % | ||||
17 | Benzoic acid, 4,4-((6-((4-(((1,1-dimethylethyl)amino)carbonyl)phenyl)amino)-1,3,5-triazine-2,4-diyl)diimino)bis-, bis (2-ethylhexyl) ester/Iscotrizinol (USAN) | Diethylhexyl Butamido Triazone | 154702-15-5 | 10 % | ||||
18 | 3-(4-Methylbenzylidene)-d1 camphor/Enzacamene | 4-Methylbenzylidene Camphor | 38102-62-4/36861-47-9 | - / 253-242-6 | 4 % | |||
[ F5 ] | ||||||||
20 | 2-Ethylhexyl salicylate/Octisalate | Ethylhexyl Salicylate | 118-60-5 | 204-263-4 | 5 % | |||
21 | 2-Ethylhexyl 4-(dimethylamino)benzoate/Padimate O (USAN:BAN) | Ethylhexyl Dimethyl PABA | 21245-02-3 | 244-289-3 | 8 % | |||
22 | 2-Hydroxy-4-methoxybenzophenone-5-sulfonic acid and its sodium salt/Sulisobenzone | Benzophenone-4, Benzophenone-5 | 4065-45-6/6628-37-1 | 223-772-2 / - | 5 % (as acid) | |||
23 | 2,2'-Methylene-bis(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethyl-butyl)phenol) / Bisoctrizole | Methylene Bis-Benzotriazolyl Tetramethylbutylphenol | 103597-45-1 | 403-800-1 | 10 % | |||
24 | Sodium salt of 2,2'-bis(1,4-phenylene)-1H-benzimidazole-4,6-disulfonic acid) / Bisdisulizole disodium (USAN) | Disodium Phenyl Dibenzimidazole Tetrasulfonate | 180898-37-7 | 429-750-0 | 10 % (as acid) | |||
25 | 2,2'-(6-(4-Methoxyphenyl)-1,3,5-triazine-2,4-diyl)bis(5-((2-ethylhexyl)oxy)phenol) / Bemotrizinol | Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine | 187393-00-6 | 10 % | ||||
26 | Dimethicodiethylbenzalmalonate | Polysilicone-15 | 207574-74-1 | 426-000-4 | 10 % | |||
[F127 | Titanium dioxide b | Titanium Dioxide | 13463-67-7/ 1317-70-0/ 1317-80-2 | 236-675-5/ 215-280-1/ 215-282-2 | 25 % d | ] | ||
[F327a | Titanium dioxide b | Titanium Dioxide (nano) | 13463-67-7/ 1317-70-0/ 1317-80-2 | 236-675-5/ 215-280-1/ 215-282-2 | 25 % d | Not to be used in applications that may lead to exposure of the end-user's lungs by inhalation Only nanomaterials having the following characteristics are allowed:
| ] | |
[F428 | Benzoic acid, 2-[-4-(diethylamino)-2-hydroxybenzoyl]-. Hexylester | Diethylamino Hydroxy benzoyl Hexyl Benzoate | 302776-68-7 | 443-860-6 | 10 % | ] | ||
[F6 [X129 | 1,3,5-Triazine, 2,4,6-tris[1,1'-biphenyl]-4-yl-, including as nanomaterial | Tris-biphenyl triazine Tris-biphenyl triazine (nano) | 31274-51-8 | — | 10 % | Not to be used in sprays. Only nanomaterials having the following characteristics are allowed:
| ] ] | |
[F230 | Zinc oxide | Zinc Oxide | 1314-13-2 | 215-222-5 | 25 % c | Not to be used in applications that may lead to exposure of the end-user's lungs by inhalation. | ||
30a | Zinc oxide | Zinc Oxide (nano) | 1314-13-2 | 215-222-5 | 25 % c | Not to be used in applications that may lead to exposure of the end-user's lungs by inhalation. Only nanomaterials having the following characteristics are allowed:
| ] |
Editorial Information
X1 Substituted by Corrigendum to Commission Regulation (EU) No 866/2014 of 8 August 2014 amending Annexes III, V and VI to Regulation (EC) No 1223/2009 of the European Parliament and the Council on cosmetic products (Official Journal of the European Union L 238 of 9 August 2014).
Textual Amendments
F1 Substituted by Commission Regulation (EU) 2016/1143 of 13 July 2016 amending Annex VI to Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products (Text with EEA relevance).
F2 Inserted by Commission Regulation (EU) 2016/621 of 21 April 2016 amending Annex VI to Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products (Text with EEA relevance).
F3 Inserted by Commission Regulation (EU) 2016/1143 of 13 July 2016 amending Annex VI to Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products (Text with EEA relevance).
F4 Substituted by Commission Regulation (EU) No 344/2013 of 4 April 2013 amending Annexes II, III, V and VI to Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products (Text with EEA relevance).
The Whole Regulation you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: